클로로펜타플루오로에탄

Excerpt from ERG Guide 126 [Gases - Compressed or Liquefied (Including Refrigerant Gases)]:

In case of fire in the surroundings, use appropriate extinguishing media. In case of fire: keep cylinder cool by spraying with water.

Fresh air, rest. Artificial respiration may be needed. Refer for medical attention.

ON FROSTBITE: rinse with plenty of water, do NOT remove clothes. Refer for medical attention .

First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.

· CALL 911. Then call emergency response telephone number on shipping paper. If shipping paper not available or no answer, refer to appropriate telephone number listed on the inside back cover.

· Do not touch or walk through spilled material.

Excerpt from NIOSH Pocket Guide for Chloropentafluoroethane:

General First Aid:

(General first aid procedures)

If material on fire or involved in fire: Extingiush fire using agent suitable for type of surrounding fire. (Material itself does not burn or burns with difficulty.) Cool all affected containers with flooding quantities of water. Apply water from as far a distance as possible.

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.

Because of recent discovery of potential ozone decomposition in the stratosphere by fluorotrichloromethane, this material should be released to the environment only as a last resort. Waste material should be /recovered and/ returned to the vendor, or to licensed waste disposal company.

... The combination of fluorocarbon with a sympathomimetic bronchodilator is potentially dangerous for the treatment of bronchial asthma. For the same reason, sympathomimetic drugs are contraindicated in cardiac resuscitation of patients suffering from fluorocarbon poisoning. /Fluorocarbon poisoning/

/In humans/ a 10 to 90% mixture of CFC-11 & CFC-12, respectively, caused more severe respiratory effects than either fluorocarbon inhaled singly.

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 200(SRC), determined from a structure estimation method(2), indicates that chloropentafluoroethane is expected to have high mobility in soil(SRC). Volatilization of chloropentafluoroethane from moist soil surfaces is expected to be an important fate process(SRC) given an estimated Henry's Law constant of 5.6 atm-cu m/mole(SRC), based upon its vapor pressure, 6860 mm Hg(3), and water solubility, 58 mg/L(4). Chloropentafluoroethane is expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(3). Highly chlorinated/fluorinated compounds such as chloropentafluoroethane are not expected to biodegrade rapidly(5).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 200(SRC), determined from a structure estimation method(2), indicates that chloropentafluoroethane is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is(3) based upon an estimated Henry's Law constant of 5.6 atm-cu m/mole(SRC), derived from its vapor pressure, 6860 mm Hg(4), and water solubility, 58 mg/L(5). Using this Henry's Law constant and an estimation method(3), volatilization half-lives for a model river and model lake are 4 hours and 5 days, respectively(SRC). According to a classification scheme(6), an estimated BCF of 20(SRC), from an estimated log Kow of 2.47(7) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Highly chlorinated/fluorinated compounds such as chloropentafluoroethane are not expected to biodegrade rapidly(9).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), chloropentafluoroethane, which has a vapor pressure of 6860 mm Hg at 25 °C(2), is expected to exist solely as a gas in the ambient atmosphere. Gas-phase chloropentafluoroethane is essentially inert in the troposphere(3). Chlorpentafluoroethane will gradually diffuse into the stratosphere above the ozone layer where it will slowly degrade due to direct photolysis from UV-C radiation and contribute to the catalytic removal of stratospheric ozone(3). The atmospheric lifetime of this compound has been estimated at 330 years(4).

The substance can be absorbed into the body by inhalation.

inhalation, skin and/or eye contact (liquid)

Suffocation.

ON CONTACT WITH LIQUID: FROSTBITE.

See Skin.

dyspnea (breathing difficulty); dizziness, incoordination, narcosis; nausea, vomiting; heart palpitations, cardiac arrhythmias, asphyxia; liquid: frostbite, dermatitis

Using a structure estimation method based on molecular connectivity indices(1), the Koc of chloropentafluoroethane can be estimated to be 200(SRC). According to a classification scheme(2), this estimated Koc value suggests that chloropentafluoroethane is expected to have moderate mobility in soil.

RURAL/REMOTE: Chloropentafluoroethane was detected in the troposphere at an average global concentration of 4.1 parts per trillion(1). The concentration of chloropentafluoroethane in the atmosphere at altitudes ranging from about 10 to 34 km was found to be approximately 1-5 parts per trillion during 1979 and 1980 monitoring(2,3).

/HUMAN EXPOSURE STUDIES/ /Propellant /fluorocarbon/ gases were generated ... from a distance of 50 cm for periods of 15 to 60 seconds. At a measured concentration of 95,000 mg/cu m (1700 ppm), there was biphasic change in ventilatory capacity, the first reduction occurring within few min after exposure, & second delayed until 13 to 30 min after exposure. Most subjects developed bradycardia, & inversion of the t-wave. /Propellant gases/

/SIGNS AND SYMPTOMS/ Early ... human experience indicated that high vapor concn (eg, 20%) may cause confusion, pulmonary irritation, tremors & rarely coma, but that these effects were generally transient & without late sequelae. Cause of death /from abuse of fluorocarbons/ is in considerable doubt. Freezing of airway soft tissues can probably be eliminated as a cause of death except in cases where the product was sprayed directly into the mouth from its container or from a balloon containing some liquid. Laryngeal spasm or edema, oxygen displacement, or sensitization of myocardium to endogenous catecholamines with subsequent ventricular fibrillation appear to be reasonable possibilities. /Fluorocarbon refrigerants & propellants/

/SIGNS AND SYMPTOMS/ Non-occupational exposure and accidental or abusive inhalation of aerosols /due to Fluorocarbon propellants/ have also been documented, the main symptoms being CNS depression and cardiovascular reactions. Cardiac arrhythmia, possibly aggravated by elevated levels of catecholamines due to stress or by moderate hypercapnia, is suggested as the cause of these adverse response, which may lead to death.

/SIGNS AND SYMPTOMS/ ... High vapor concn (eg, 20%) may cause confusion, pulmonary irritation, tremors & rarely coma ... but ... these effects were generally transient & without late sequelae. /Fluorocarbon refrigerants & propellants/

For more Human Toxicity Excerpts (Complete) data for CHLOROPENTAFLUOROETHANE (12 total), please visit the HSDB record page.

The Food and Drug Administration (FDA), after consultation with the Environmental Protection Agency (EPA), is amending FDA's regulation on the use of ozone-depleting substances (ODSs) in selfpressurized containers to remove the essential-use designations for flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil used in oral pressurized metered-dose inhalers (MDIs). The Clean Air Act requires FDA, in consultation with the EPA, to determine whether an FDA-regulated product that releases an ODS is an essential use of the ODS. FDA has concluded that there are no substantial technical barriers to formulating flunisolide, triamcinolone, metaproterenol, pirbuterol, albuterol and ipratropium in combination, cromolyn, and nedocromil as products that do not release ODSs, and therefore they will no longer be essential uses of ODSs as of the effective dates of this rule. MDIs for these active moieties containing an ODS may not be marketed after the relevant effective date. DATES: Removal of Part 2.125(e)(2)(iii) and 2.125(e)(4)(vii) is effective June 14, 2010. Removal of Part 2.125(e)(1)(v) and 2.125(e)(4)(iv) is effective December 31, 2010. Removal of Part 2.125(e)(1)(iii) is effective June 30, 2011. Removal of 2.125(e)(2)(iv) and Part 2.125(e)(4)(viii) is effective December 31, 2013. /Ozone-Depleting Substances/

Use of ozone-depleting substances in foods, drugs, devices, or cosmetics. (a) As used in this section, ozone-depleting substance (ODS) means any class I substance as defined in 40 CFR part 82, appendix A to subpart A, or class II substance as defined in 40 CFR part 82, appendix B to subpart A. (b) Except as provided in paragraph (c) of this section, any food, drug, device, or cosmetic that is, consists in part of, or is contained in an aerosol product or other pressurized dispenser that releases an ODS is not an essential use of the ODS under the Clean Air Act. (c) A food, drug, device, or cosmetic that is, consists in part of, or is contained in an aerosol product or other pressurized dispenser that releases an ODS is an essential use of the ODS under the Clean Air Act if paragraph (e) of this section specifies the use of that product as essential. For drugs, including biologics and animal drugs, and for devices, an investigational application or an approved marketing application must be in effect, as applicable. ... (e) The use of ODSs in the following products is essential: ... (2) Metered-dose short-acting adrenergic bronchodilator human drugs for oral inhalation. Oral pressurized metered-dose inhalers containing the following active moieties: ... (iv) Pirbuterol. ... (4) Other essential uses. (iii) Anesthetic drugs for topical use on accessible mucous membranes of humans where a cannula is used for application. ... (vi) Metered-dose atropine sulfate aerosol human drugs administered by oral inhalation. ... (viii) Metered-dose ipratropium bromide and albuterol sulfate, in combination, administered by oral inhalation for human use. (ix) Sterile aerosol talc administered intrapleurally by thoracoscopy for human use. /Ozone-Depleting Substances/

The food additive chloropentafluoroethane may be safely used in food in accordance with the following prescribed conditions: (a) The food additive has a purity of not less than 99.97 percent, and contains not more than 200 parts per million saturated fluoro compounds and 10 parts per million unsaturated fluoro compounds as impurities. (b) The additive is used or intended for use alone or with one or more of the following substances: Carbon dioxide, nitrous oxide, propane, and octafluorocyclobutane complying with part 173.360, as an aerating agent for foamed or sprayed food products, with any propellant effect being incidental and no more than is minimally necessary to achieve the aerating function, except that use is not permitted for those standardized foods that do not provide for such use. (c) To assure safe use of the additive (1) The label of the food additive container shall bear, in addition to the other information required by the act, the following: (i) The name of the additive, chloropentafluoroethane. (ii) The percentage of the additive present in the case of a mixture. (iii) The designation "food grade". (2) The label or labeling of the food additive container shall bear adequate directions for use.